Tesla gains as Musk buys $1 billion in stock; closes well-off highs
Boston Scientific Corporation (NYSE:BSX), a prominent player in the Healthcare Equipment & Supplies industry with a market capitalization of approximately $159 billion, announced that Jeffrey B. Mirviss, Executive Vice President and President of Peripheral Interventions, has decided to retire from his current role effective December 1, 2025. The news was disclosed in a press release statement based on a filing with the Securities and Exchange Commission.
According to the company, Mirviss will remain with Boston Scientific as a senior advisor from December 1, 2025, through February 27, 2026, or an earlier date if determined. During this period, he will receive a base salary prorated from his current annual rate of $705,000. The company has demonstrated strong financial performance, with revenue growing by 21% in the last twelve months to $18.5 billion.
Boston Scientific stated it expects to enter into a Retirement Agreement with Mirviss effective as of his final retirement date. Under this agreement, Mirviss will be entitled to payments and benefits consistent with the company’s Executive Retirement Plan, 2025 Annual Bonus Plan, and Long-Term Incentive Program, as well as equity awards previously disclosed in filings with the SEC.
The company did not announce a successor or provide additional details regarding the transition in the filing. Boston Scientific is headquartered in Marlborough, Massachusetts, and its common stock and 0.625% Senior Notes due 2027 are listed on the New York Stock Exchange. The stock is currently trading near its 52-week high of $108.94, reflecting investor confidence. For detailed analysis and additional insights, check out the comprehensive Pro Research Report available on InvestingPro, where you’ll find 16 more exclusive ProTips about Boston Scientific’s performance and outlook.
All information is based on a press release statement included in the company’s recent SEC filing.
In other recent news, Boston Scientific has reported impressive financial results, with a 17% year-over-year organic revenue growth and a 23% increase in earnings per share, according to RBC Capital. Additionally, the company achieved 17.4% organic sales growth in Q2, with notable performances in its electrophysiology division and Watchman product line, as highlighted by Bernstein SocGen Group. Despite these strong results, the FDA has disclosed a potentially high-risk issue with Boston Scientific’s ENDOTAK RELIANCE Defibrillation leads, linked to patient deaths, and is part of an effort to enhance the Medical Device Recall Program.
Several analyst firms have raised their price targets for Boston Scientific following these developments. Truist Securities increased its target to $125, citing a strong quarter with multiple tailwinds. RBC Capital also raised its target to $125, noting the company’s earnings beat and robust growth. Bernstein SocGen Group adjusted its target to $130, driven by significant growth in the company’s electrophysiology division. Mizuho went further, setting a new target of $140, expecting strong performances in the FARAPULSE and WATCHMAN lines to offset challenges from a global recall of the ACURATE TAVR system.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.